MetaCap

Aptevo Therapeutics (APVO) vs PMGC (ELAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aptevo Therapeutics is the larger company by market cap ($1.4 million vs $1.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APVO-78.04%ELAB-63.69%
+4%-39%-82%
Oct 7, 20261 yearNov 20, 2026
APVO-77.42%ELAB-62.99%
+4%-39%-81%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APVO versus ELAB key metrics
MetricAPVOELAB
Share price$0.4041$1.14
Market cap$1.40M$1.33M
1-day change-2.37%-10.24%
P/E ratio (TTM)0.01—
EPS (TTM)$66.96$-555.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$590.08K
Net income (latest FY)$-25.97M$-7.75M
Gross margin—31.40%
Net margin—-1313.00%
52-week high$25.56$1,344.00
52-week low$0.377$1.14
Distance from 52-week high-98.42%-99.92%
Analyst consensusnone—
Avg. price target upside+6210.32%—
Average volume132.90K279.01K
Shares outstanding3.46M1.17M
Employees3332
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aptevo Therapeutics

APVO stock →

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About PMGC

ELAB stock →

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees

APVO vs ELAB FAQ

Which is bigger, Aptevo Therapeutics or PMGC?

Aptevo Therapeutics (APVO) is larger, with a market capitalization of $1.40M compared with $1.33M for PMGC (ELAB).

Are Aptevo Therapeutics and PMGC in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons